Nektar Therapeutics (NKTR) Cost of Revenue (2010 - 2026)

Nektar Therapeutics' Cost of Revenue history runs 17 years deep, the most recent figure standing at $7.7 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 55.38% year-over-year to $7.7 million; the TTM figure through Mar 2026 stood at $18.0 million (down 69.41% YoY), while the FY2024 annual figure was $42.0 million, up 13.49% from the prior year.
• Cost of Revenue for Q1 2026 stood at $7.7 million, down from $10.3 million in the prior quarter.
• The five-year high for Cost of Revenue was $19.3 million in Q4 2024, with the low at $5.0 million in Q3 2022.
• The 5-year median for Cost of Revenue is $10.3 million (2025), against an average of $9.8 million.
• The sharpest annual moves came in 2023 and 2026: Cost of Revenue jumped 150.02% in 2023, then sank 55.38% in 2026.
• Nektar Therapeutics' Cost of Revenue stood at $6.2 million in 2022, then surged by 69.47% to $10.6 million in 2023, then soared by 83.07% to $19.3 million in 2024, then tumbled by 46.75% to $10.3 million in 2025, then fell by 25.2% to $7.7 million in 2026.
• Business Quant data shows NKTR's Cost of Revenue at $7.7 million in Q1 2026, $10.3 million in Q3 2025, and $17.3 million in Q1 2025.